Literature DB >> 33210232

Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.

Francesca Gensini1, Roberta Sestini1, Alessandro De Luca2, Valentina Pinna2, Paola Daniele2, Lorenzo Orzalesi3, Maria Cristina Petrella4, Berardino Porfirio1, Laura Papi5.   

Abstract

We present a 24-year-old female patient affected by neurofibromatosis type 1 (NF1) who developed a malignant phyllodes tumor of the breast. The molecular studies showed that the patient carried a heterozygous inactivating deleterious variant in BRCA1 inherited from the father associated with a germline de novo pathogenic alteration in NF1; the tumor presented a biallelic inactivation of both genes. Therefore, tumor analyses helped to establish that the germline NF1 and BRCA1 variants were in cis on the paternal chromosome. This last information is important to provide adequate genetic counselling regarding the risk of recurrence in the offspring, as well as opportunity for early intervention. In conclusion, we present the first case of a malignant phyllodes tumor of the breast in patient carrying pathogenic variants in NF1 and BRCA1. Further studies will be necessary to understand if the phyllodes histotype represents a very rare component of NF1-associated breast cancer.

Entities:  

Keywords:  BRCA1; Breast cancer.; Malignant phyllodes tumor; NF1; Neurofibromatosis type 1

Mesh:

Year:  2020        PMID: 33210232     DOI: 10.1007/s10689-020-00217-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  1 in total

1.  Breast lesions in generalized neurofibromatosis: breast cancer and cystosarcoma phylloides.

Authors:  M D el-Zawahry; M Farid; A Abd el-Latif; H Horeia; M el-Gindy; G Twakal
Journal:  Neurofibromatosis       Date:  1989
  1 in total
  1 in total

Review 1.  Phyllodes Tumors: A Scoping Review of the Literature.

Authors:  Jessica Bogach; Saad Shakeel; Frances C Wright; Nicole J Look Hong
Journal:  Ann Surg Oncol       Date:  2021-07-22       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.